U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
BETHLEHEM, Pa., May 10, 2017 -- B. Braun Medical Inc. will introduce Prontosan® Wound Gel X, a wound care gel, at the 49th Annual Wound, Ostomy and Continence Nurses (WOCN) Conference.
“Gel X is the only wound gel with both betaine and the preservative polyhexanide, a potent microbial barrier that creates a favorable wound healing environment to prevent recontamination,” said Mike Kelly, Director of Marketing for Infection Control Products at B. Braun Medical. “The product is designed with comfort and healing in mind and to ease the journey from hospital to home.”
Highly viscous, clear and odorless, Prontosan Wound Gel X is designed to cleanse and moisten wound beds and contains betaine, a surfactant that promotes removal of dirt and debris, aids in removal of wound coating, and helps prevent recontamination. Combined with polyhexanide, it is an effective microbial barrier.
Compatible with many secondary dressings, it eliminates needless dressing changes and aids in the removal of wound coatings.
“Case studies have shown that in 74 percent of burn cases where this product was used, burns healed without secondary infections,” Kelly said. “Additionally, 100 percent of case patients reported good comfort during treatment and found the application easy.”1
Prontosan Wound Gel X will be presented along with B. Braun’s ostomy product line at the WOCN conference from May 20 - 22 at the Calvin L. Rampton Salt Palace Convention Center in Salt Lake City, Utah. B. Braun will be at booth #1033.
About B. Braun
B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®.
Globally, the B. Braun Group of Companies employs more than 58,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.
1 Data on file
Contact: Jason Ford B. Braun Medical Inc. 610.997.4722 [email protected]
